Tomosynthesis After Screening Mammography May Reduce Recall Rates
Fewer ultrasounds and biopsies were seen for women referred for breast tomosynthesis after recall for focal asymmetric density following screening mammography.
Performing breast tomosynthesis among women recalled for focal asymmetric density after a screening mammography results in fewer ultrasounds, fewer biopsies and higher positive predictive value (PPV) for cancer, according to a study presented today at the 2014 ARRS Annual Meeting in San Diego, Calif.
“Tomosynthesis has been evaluated in screening populations and been shown to decrease recall rates, but studies in the diagnostic setting are lacking,” researcher Brandi Nicholson said in a release.
To address this issue, researchers from the University of Virginia in Charlottesville compared tomosynthesis to 2D diagnostic imaging for 532 women recalled for a focal asymmetric density (FAD) at screening. The researchers retrospectively reviewed patients who had been recalled from screening for both one and two view FAD in three groups: 238 in the pre-tomo group (PT) from July to October 2011, 145 in a no-tomo (NT) and 149 in a yes-tomo (YT) group from April to July 2012 imaged and interpreted at their institution. Tomo imaging was dual acquisition.
The findings showed that ultrasounds were performed significantly less often in the YT group than in both the PT group and the NT group. However the number of ultrasounds was similar for the PT and NT groups. In addition, the researchers found that the PPV was increased in the YT group, compared with both the PT and NT groups.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
